Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relating perivascular imaging measures to longitudinal lesion evolution and chronic inflammation in multiple sclerosis.

Multiple sclerosis and related disorders·2026
Same author

A multifactorial investigation of 90-day readmission risk in thoracolumbar burst fractures: Does surgery play a role?

North American Spine Society journal·2026
Same author

Biologic immunomodulators and spinal fusion: evidence, mechanisms, and perioperative considerations.

European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society·2026
Same author

Death after Total Hip Arthroplasty in Patients with Compensated Heart Failure: Retrospective Cohort Study.

Hawai'i journal of health & social welfare·2026
Same author

BK Channels Orchestrate Cardiac Homeostasis Through Mitochondrial Uncoupling Proteins.

bioRxiv : the preprint server for biology·2026
Same author

Ultra-low-field MRI for bedside imaging of severe multiple sclerosis.

Journal of neurology·2026
Same journal

Emapalumab plus conventional therapy with or without ruxolitinib for pediatric hemophagocytic lymphohistiocytosis: a single center retrospective study.

Immunologic research·2026
Same journal

Immunological spectrum in patients with thymoma: beyond good syndrome.

Immunologic research·2026
Same journal

Microbiome immune crosstalk in Sjögren's syndrome: mechanistic insights and translational perspectives.

Immunologic research·2026
Same journal

Immune checkpoint inhibitor-induced myasthenia gravis and myocarditis: a fatal immune-related adverse event.

Immunologic research·2026
Same journal

TRIM28 and TRIM32: multifaceted regulators of innate immunity and antiviral defence.

Immunologic research·2026
Same journal

Decoding PANoptosis: Crosstalk of cell death pathways in immunity and inflammation.

Immunologic research·2026
See all related articles

Related Experiment Video

Updated: Apr 8, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.2K

High-mobility group box 1 in multiple sclerosis.

Zohara Sternberg1, Daniel Sternberg2, Trevor Chichelli2

  • 1Department of Neurology, Baird MS Center, Jacobs Neurological Institute, Buffalo, NY, USA. zs2@buffalo.edu.

Immunologic Research
|June 24, 2015
PubMed
Summary
This summary is machine-generated.

Serum levels of High-Mobility Group Box 1 (HMGB1) are elevated in treatment-naïve multiple sclerosis (MS) patients compared to treated patients and healthy controls. HMGB1 may serve as a biomarker for MS clinical relapse.

Keywords:
BiomarkerClinical relapseCytokineDisease-modifying drugInflammationNecrosis

More Related Videos

Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier
09:00

Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier

Published on: April 5, 2017

21.0K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

10.1K

Related Experiment Videos

Last Updated: Apr 8, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.2K
Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier
09:00

Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier

Published on: April 5, 2017

21.0K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

10.1K

Area of Science:

  • Neuroimmunology
  • Biomarker Discovery
  • Multiple Sclerosis Pathogenesis

Background:

  • The receptor for advanced glycation end products (RAGE) axis is implicated in multiple sclerosis (MS) pathogenesis.
  • High-Mobility Group Box 1 (HMGB1) is a ligand of RAGE, and its role in MS requires further elucidation.

Purpose of the Study:

  • To evaluate serum HMGB1 levels in MS patients.
  • To assess the correlation between HMGB1 levels and disease-modifying drug (DMD) use in MS.
  • To investigate the relationship between HMGB1 levels and MS disease severity indicators, including clinical relapse.

Main Methods:

  • Serum HMGB1 levels were quantified using enzyme-linked immunosorbent assays (ELISAs).
  • HMGB1 levels were compared between 96 MS patients (23 males) and 34 age- and gender-matched healthy controls (HCs).
  • Correlations with DMD status and clinical MS status (relapse vs. stable) were analyzed.

Main Results:

  • DMD-naïve MS patients exhibited significantly higher serum HMGB1 levels than DMD-treated MS patients (P=0.04) and HCs (P=0.01).
  • No significant difference in HMGB1 levels was observed between the total MS patient cohort (DMD-naïve and treated) and HCs (P=0.09).
  • A trend suggested lower HMGB1 levels in DMD-naïve MS patients experiencing clinical relapse compared to stable RRMS patients (P=0.07). HMGB1 demonstrated 0.65 AUC for MS clinical relapse prediction.

Conclusions:

  • Serum HMGB1 levels are elevated in treatment-naïve MS patients, suggesting a potential role in early disease stages.
  • HMGB1 may serve as a potential biomarker for predicting MS clinical relapse.
  • Further research is warranted to explore HMGB1's role in MS pathology and the impact of DMDs on its modulation.